Fact based stock research
MediGene (XTRA:MDG1)


MediGene stock research in summary

medigene.de


MediGene shares have a SELL rating. They show below average growth, are riskily financed, and are bad value. We recommend selling MediGene shares.


Latest Obermatt Ranks


Country Germany
Industry Biotechnology
Index TecDAX, CDAX
Size class X-Small

June 8, 2018. Top 10 stocks updated on Top 10 schedule or at least quarterly. ()


Research History: MediGene

STOCK RESEARCH SUMMARY 2015 2016 2017 2018
STOCK VALUE RANKS
9
11
1
8
STOCK GROWTH RANKS
83
38
92
44
STOCK SAFETY RANKS
73
51
61
29
COMBINED STOCK RANKS
73
17
53
11

Last update of Combined Rank: 8-Jun-2018. Stock research history is based on the Obermatt Method. The higher the rank, the better is MediGene in the corresponding investment strategy.


Value Metrics in Detail

Last update of Value Rank: 8-Jun-2018. Stock analysis on value ratios: The higher the rank, the lower the value ratio of MediGene; except for dividend yield where the rank is higher, the higher the yield.


Growth Metrics in Detail

GROWTH METRICS 2015 2016 2017 2018
REVENUE GROWTH
6
34
96
12
PROFIT GROWTH
92
92
92
66
STOCK RETURNS
90
89
85
68
CONSOLIDATED RANK: GROWTH
83
38
92
44

Financial reporting date of Growth Rank: 31-Mar-2018. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of MediGene.


Safety Metrics in Detail

SAFETY METRICS 2015 2016 2017 2018
LEVERAGE
93
85
85
79
REFINANCING
71
40
40
36
LIQUIDITY
79
25
28
23
CONSOLIDATED RANK: SAFETY
73
51
61
29

Financial reporting date of Safety Rank: 31-Mar-2018. Stock analysis on safety metrics: The higher the rank, the lower the leverage of MediGene and the more cash is available to service its debt.


Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for MediGene from June 8, 2018.